EuroBiotech: More Articles of Note

Newspapers

> Argenx pulled off an $100 million (€90 million) Nasdaq IPO. The fundraising haul came in above argenx’s initial target, largely because it offered more shares than originally planned. Argenx will use the cash to take its autoimmune candidate ARGX-113 to the start of a phase 3 trial. Release

> Verona Pharma sold off part of the over-allotment offered in its Nasdaq IPO. The sale of the stock added $9.3 million to Verona’s gross fundraising total. Verona went public in the U.S. to fund midphase trials in chronic obstructive pulmonary disease and cystic fibrosis. Statement

> Alcobra parted company with its CEO. Yaron Daniely, Ph.D. is stepping down at the end of the month to take the top job at tech transfer company Yissum, ending his seven-year stint as CEO of Alcobra. Chief commercial officer David Baker is taking over as CEO on an interim basis. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Cinfa Biotech posted top-line data from a clinical trial of its biosimilar copy of Amgen’s Neulasta. The Spanish biotech said the pharmacodynamics and immunogenicity of its copycat matched up to Neulasta, teeing it up to file for approval in Europe in the second half of the year. Statement

> AptaTargets raised €2.7 million to move its treatment for acute ischemic stroke into a phase 1/2 trial. Caixa Capital Risc and Inveready put up the money. AptaTargets will use the money to wrap up preclinical development of its aptamer candidate. Release

> Shares in Nanobiotix climbed following the publication of data on NBTXR3. The data linked the NBTXR3 to an uptick in immune cell infiltration, boosting expectations that the radio enhancer can make “cold” tumors “hot.” Statement

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.